Table 3.

Review of Studies Examining Metabolic Syndrome in Patients Treated with HCT

Study	Year	n	Age	Source (n)	Median Time after HCT, yr	Treated with TBI, %	MetSyn, %	Other
Taskinen M et al. [13]	2000	23	10-32	Allo	10.8	78	39
Shalitin et al. [16]	2006	91	4-32	Allo (45), auto (46)	6.2 (mean)	16	ND	27.9% of tested patients with dyslipidemia
Taskinen M et al. [17]	2007	31	7-34	Allo	6	90	39	48% developed GH deficiency (75% of individuals with MetSyn)
Chow EJ et al. [11]	2010	26	8-21	Allo	6	100	23	38.5% treated with cranial radiation, 50% developed GH deficiency
Oudin C et al. [15]	2011	60	18-41	Allo (39), auto (21)	15.4	72	15
Bajwa R et al. [10]	2012	160	5-28	Allo (99) Auto (70)	7	37	7.5	17% developed GH deficiency
Frisk P et al. [12]	2012	18	17-37	Allo (3), auto (15)	18.2	100	17	39% treated with cranial radiation
Paris C et al. [18]	2012	69	6-25	Allo (59), auto (10)	4	55	32	Low HDL most common component. Corticosteroid use before or after post-HCT was most significant risk factor for MetSyn.
Bizzarri C et al. [14]	2015	45	13.9 ± 4.8	Allo (40), auto (5)	4-6.9 (mean)	47	0
Oudin C et al. [19]	2015	170	24.8 ± 5.4	Allo (124), auto (46)	14.5 (mean)	73	17	9% treated with cranial/craniospinal radiation; GH deficiency associated with increased MetSyn risk
Higgins K et al. [20]	2005	16	25-54	Allo (13), auto (3)	6 (mean)	93	25	Hypertriglyceridemia most common
Annaloro C et al. [9]	2008	85	26-63	Allo (39), auto (46)	9	78	34	Hypertriglyceridemia most common
Majhail NS et al. [21]	2009	86	21-71	Allo	3	77	49	Hypertriglyceridemia most common
McMillen KK et al. [22]	2014	785	18-74	Allo		48	34% pre-HCT 40% modified MetSyn at 1 yr	Hypertriglyceridemia most common

Allo indicates allogeneic; auto, autologous; ND, not defined; GH, growth hormone.